Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Inclusion Criteria * Scheduled to undergo major, open abdominal-pelvic surgery for known or presumed gynecologic malignancy * Age 18 years or older at the time of signing the consent * Gynecologic Oncology Group (GOG) performance status of ≤ 2 * Life expectancy of \> 3 months * Patient's weight must be ≥ 50 kg * Adequate organ function within 28 days of study entry defined as: * Hemoglobin ≥ 9.0 g/dL * Platelet ≥ 100,000 x 109/L * Blood urea nitrogen (BUN) ≤ 30 mg/dL * Serum creatinine ≤ 1.5 mg/dL * Not pregnant as determined by a negative urine or serum pregnancy test within 14 days of study enrollment * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Exclusion Criteria * Current treatment with anticoagulants * Thromboembolism within the previous 6 months * Bleeding/blood disorders (e.g., thrombocytopenia), gastrointestinal bleeding (e.g., active ulcers), history of stroke within past 3 years, or severe and currently uncontrolled high blood pressure * Bacterial endocarditis * Known hypersensitivity to fondaparinux sodium